Rivaroxaban

Amber-G

Brand Name(s):Xarelto

Indication:DVT & PE – treatment. Atherothrombotic events (prevention) in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.
Atherothrombotic events (prevention of) in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD).

Rationale:

Considered:Nov-12

Review Date:Nov-24

Comments:
NICE TA607 – Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease ………………………… Drug Safety Update
Rivaroxaban : reminder that 15 mg and 20 mg tablets should be taken with food
Jul-19
…………………………
Drug Safety Update
Rivaroxaban treatment in patients who undergo transcatheter aortic valve replacement (TAVR) should be stopped and switched to standard of care.
Oct-18
NICE TA335
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Full document available at:https://www.nice.org.uk/guidance/ta335/resources/guidance-rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome-pdf
March 2015